Table 2

Prevalence of VPAC1, VPAC2, and PAC1 receptors in selected human tumors

Tumor type (n)VPAC1n (%)VPAC2n (%)PAC1n (%)
Gastric cancer, diffuse type (9)1 (11) *2 (22) *0
Gastric cancer, intestinal type (8)4 (50) *5 (62) *0
Colorectal adenocarcinoma (5)4 (80)02 (40)
Pancreatic ductal adenocarcinoma (5)5 (100)00
Hepatocellular carcinoma (10)4 (40) *3 (30) *0
Breast cancer (4)4 (100)2 (50)4 (100)
Ovarian carcinoma (10)3 (30)2 (20)3 (30)
Prostate cancer (4)3 (75)1 (25)0
Thyroid cancer (6)000
Carcinoid (15)6 (40)8 (53)8 (53)
Pancreatic insulinoma (8)3 (38)4 (50)3 (38)
Pituitary adenoma, growth-hormone-producing (2)2 (100)02 (100)
Pituitary adenoma, non-functional (2)1 (50)02 (100)
Pheochromocytoma (2)01 (50)2 (100)
Glioblastoma multiforme (4)4 (100)4 (100)4 (100)
Meningioma (4)2 (50)4 (100)3 (75)
  • * <10% of the tumor cells showed membranous expression of either VPAC1, VPAC2, or PAC1.